Dopamine D3/D2 receptor (partial agonist)
Assets acting on this target.
- Class
- Dopamine partial agonist
The dopamine D2 and D3 receptors are G-protein-coupled receptors that respond to the neurotransmitter dopamine and are central to the regulation of mood, motivation, and thought organization. In several psychiatric conditions, including schizophrenia and bipolar disorder, dopamine signaling is thought to be unevenly distributed across brain circuits, with excess activity in some pathways and deficient activity in others. A partial agonist at these receptors binds the same site as dopamine but produces a submaximal response, meaning it can act as a functional antagonist where dopamine tone is high and as a mild stimulant where dopamine tone is low. This dual behavior offers a rationale for aiming to correct psychotic symptoms without inducing the low-dopamine side effects associated with full antagonism. Preferential affinity for the D3 receptor subtype, which is concentrated in limbic and mesolimbic regions associated with reward and emotional processing, is intended to target circuits relevant to mood and motivation more selectively than uniform D2 blockade would. This class of molecule is relevant broadly to psychotic and mood disorders where dopaminergic imbalance is implicated, and the partial-agonist, D3-preferring profile represents one strategy for balancing efficacy against movement-related and hormonal side effects common to older dopamine-blocking agents.
By indication
Related mechanisms
Dopamine D3/D2 receptor (partial agonist) drugs compared
5 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Cariprazine (Vraylar)Vraylar | AbbVie, Gedeon Richter, Tanabe Pharma Corporation | small molecule | Approved | Approved in Bipolar Depression; Approved in Bipolar Disorder; Approved in Major Depressive Disorder; Approved in Schizophrenia |
| Cariprazine (Chengdu Kanghong) | Chengdu Kanghong Pharmaceutical | small molecule | Phase 3 | Phase 3 in Schizophrenia |
| Cariprazine (QLM1016) | Qilu Pharmaceutical | small molecule | Phase 3 | Phase 3 in Schizophrenia |
| JX11502MA | Zhejiang Jingxin Pharmaceutical Co., Ltd. | small molecule | Phase 2 | Phase 1/2 in Schizophrenia |
| Cariprazine long-acting injection (Mapi Pharma) | Mapi Pharma | small molecule | Phase 1/2 | Phase 1/2 in Schizophrenia |